The U.S. Food and Drug Administration has granted Philip Morris International (PM) permission to market its ZYN nicotine pouches as modified risk tobacco products, marking the first such designation for smoke free pouches in the U.S.

For investors, this FDA milestone comes during a strong period for Philip Morris International, with a 19.95% 90 day share price return and a 143.58% five year total shareholder return. This suggests that recent momentum has been added to already robust long term gains.

If the ZYN decision has you considering where regulation and growth intersect, this is a good moment to scan the market using our AI infrastructure and hardware enablers screener, starting with 55 AI infrastructure stocks

Philip Morris International now trades only a few percent below both analyst price targets and an intrinsic value estimate, even after the ZYN driven jump. Is the market being cautious for good reason, or underpricing this new regulatory footing?

Most Popular Narrative: 10% Undervalued

At a last close of $193.00 versus a widely followed fair value of $193.14, the current price for Philip Morris International sits almost exactly on that narrative anchor, which is framed with a modest 10% undervaluation signal.

The accelerating global adoption of smoke-free alternatives, driven by increasing health awareness and regulatory moves away from combustibles, is associated with strong double-digit volume and margin growth in PMI's IQOS, ZYN, and VEEV platforms. This secular shift is described as enabling the company to capture new consumer segments, expand its addressable market, and structurally support higher net revenues and operating margins over time.

Curious what sits behind that fair value for Philip Morris International? The narrative leans heavily on projected revenue expansion, rising margins and a future earnings multiple that assumes smoke free products keep pulling more weight.

Result: Fair Value of $193.14 (UNDERVALUED)

However, the Philip Morris International narrative can still be challenged if cigarette volume declines outpace smoke free demand, or if future FDA and tax decisions become less supportive.

Another View on Philip Morris International’s Valuation

The fair value narrative for Philip Morris International leans on future earnings power, but the current P/E of 27.7x stands well above both the global tobacco peer average of 11.5x and a fair ratio of 26x. That premium points to higher valuation risk if expectations soften, so how comfortable are you with paying up for this story?

Next Steps

With Philip Morris International attracting mixed reactions around both risks and rewards, this is a moment to review the full picture quickly and decide where you stand using the 4 key rewards and 1 important warning sign

Looking for more ideas beyond Philip Morris International?

If this Philip Morris International update has sharpened your thinking, do not stop here. Broaden your watchlist with a few focused stock idea shortlists.

• Target dependable income and stress test your current holdings against 9 dividend fortresses that may offer more resilient cash returns.
• Hunt for quality at a potentially attractive price by scanning our 49 high quality undervalued stocks that combine fundamentals with pricing that some investors may overlook.
• Prioritise capital preservation first and see which companies clear the bar in our 79 resilient stocks with low risk scores before you commit new money.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.